Biomoneta

2 known investors

Biomoneta develops ZeBox air decontamination technology that captures and destroys airborne microorganisms, including multidrug-resistant bacteria, viruses, and fungi, in occupied spaces. Its products (Avata for homes and AvataRx for healthcare) target hospitals, labs, offices, and other environments at risk of microbial contamination in healthcare, pharmaceutical, and biotech settings.